- Details
- Description
Strength:
60 mg
Composition:
Zongertinib
Treatment:
HER2 (ERBB2) mutation-positive non-small cell lung cancer (NSCLC)
Form:
Film-coated tablets
Brand:
HERNEXEOS
Quantity Unit:
Tablets
Manufacturer:
Boehringer Ingelheim Pharmaceuticals, Inc. (for HERNEXEOS)
Zongertinib 60 mg (zongertinib) is a targeted anticancer medicine used for the treatment of certain forms of non-small cell lung cancer (NSCLC) with activating HER2 (ERBB2) mutations. Zongertinib is a selective HER2 tyrosine kinase inhibitor that works by blocking HER2 signaling pathways involved in the growth and proliferation of cancer cells.
The medicine is intended for patients whose tumors have the appropriate molecular characteristics and should be used under the supervision of a qualified healthcare professional. Appropriate molecular testing is generally required to confirm the presence of a HER2 mutation before treatment.
